Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.
We evaluated hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) expression and their prognostic significance in diffuse large B-cell lymphoma (DLBCL). Expression of HIF-1α and VEGF was studied in 78 patients and results correlated with clinicopathological and prognost...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797088248401494016 |
|---|---|
| author | Powell, JR Dojcinov, S King, L Wosniak, S Gerry, S Casbard, A Bailey, H Gallop-Evans, E Maughan, T |
| author_facet | Powell, JR Dojcinov, S King, L Wosniak, S Gerry, S Casbard, A Bailey, H Gallop-Evans, E Maughan, T |
| author_sort | Powell, JR |
| collection | OXFORD |
| description | We evaluated hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) expression and their prognostic significance in diffuse large B-cell lymphoma (DLBCL). Expression of HIF-1α and VEGF was studied in 78 patients and results correlated with clinicopathological and prognostic data. HIF-1α and VEGF were expressed in 67% and 84% of patients, respectively, and a significant correlation was demonstrated between them (p < 0.001). Outcome was analyzed according to treatment. HIF-1α positive patients given rituximab demonstrated improved outcome, with 5-year overall survival of 72% for those receiving rituximab versus 65% for those not receiving rituximab, and 5-year progression-free survival (PFS) 76% versus 57%. No correlation was demonstrated between HIF-1α and other prognostic biomarkers including BCL6, CD10 and MUM-1. We demonstrated significantly improved PFS (p = 0.003) in patients receiving rituximab and showing BCL6 overexpression. The results confirm the significant association between HIF-1α and VEGF expression and suggest that HIF-1α expression is a favorable prognostic factor in patients with DLBCL treated with rituximab. |
| first_indexed | 2024-03-07T02:47:18Z |
| format | Journal article |
| id | oxford-uuid:ac767dce-5ae5-4333-b540-97b2d7a25ab9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:47:18Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:ac767dce-5ae5-4333-b540-97b2d7a25ab92022-03-27T03:29:11ZPrognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ac767dce-5ae5-4333-b540-97b2d7a25ab9EnglishSymplectic Elements at Oxford2013Powell, JRDojcinov, SKing, LWosniak, SGerry, SCasbard, ABailey, HGallop-Evans, EMaughan, TWe evaluated hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) expression and their prognostic significance in diffuse large B-cell lymphoma (DLBCL). Expression of HIF-1α and VEGF was studied in 78 patients and results correlated with clinicopathological and prognostic data. HIF-1α and VEGF were expressed in 67% and 84% of patients, respectively, and a significant correlation was demonstrated between them (p < 0.001). Outcome was analyzed according to treatment. HIF-1α positive patients given rituximab demonstrated improved outcome, with 5-year overall survival of 72% for those receiving rituximab versus 65% for those not receiving rituximab, and 5-year progression-free survival (PFS) 76% versus 57%. No correlation was demonstrated between HIF-1α and other prognostic biomarkers including BCL6, CD10 and MUM-1. We demonstrated significantly improved PFS (p = 0.003) in patients receiving rituximab and showing BCL6 overexpression. The results confirm the significant association between HIF-1α and VEGF expression and suggest that HIF-1α expression is a favorable prognostic factor in patients with DLBCL treated with rituximab. |
| spellingShingle | Powell, JR Dojcinov, S King, L Wosniak, S Gerry, S Casbard, A Bailey, H Gallop-Evans, E Maughan, T Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. |
| title | Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. |
| title_full | Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. |
| title_fullStr | Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. |
| title_full_unstemmed | Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. |
| title_short | Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. |
| title_sort | prognostic significance of hypoxia inducible factor 1α and vascular endothelial growth factor expression in patients with diffuse large b cell lymphoma treated with rituximab |
| work_keys_str_mv | AT powelljr prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab AT dojcinovs prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab AT kingl prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab AT wosniaks prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab AT gerrys prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab AT casbarda prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab AT baileyh prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab AT gallopevanse prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab AT maughant prognosticsignificanceofhypoxiainduciblefactor1aandvascularendothelialgrowthfactorexpressioninpatientswithdiffuselargebcelllymphomatreatedwithrituximab |